Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07185399 · ClinicalTrials.gov registry record · Phase 4
Systems Biological Analysis of Immune Responses to RSV Vaccine
A Phase 4 study of Respiratory Syncytial Virus (RSV), sponsored by Emory University.
- Active
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07185399: Active Phase 4 study of Respiratory Syncytial Virus (RSV), sponsored by Emory University.
NCT07185399 is a Phase 4 study of Respiratory Syncytial Virus (RSV) that is active but no longer recruiting, run by Emory University. The registered enrollment target is 14 participants, below the 6,755-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07185399, a Phase 4 study of Respiratory Syncytial Virus (RSV), is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach. The study aims to generate high-resolution immunologic and systems biology data following vaccination to identify early biomarkers of response and gain mechanistic insight into host immunity.
Primary Outcome
The magnitude of RSV-specific antibody responses following vaccination with an mRNA RSV vaccine (MRESVIA) is assessed as antibody titers at Days 28 and 365 post-vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Moderna RSV vaccine
Study Locations (1)
Georgia
- The Hope Clinic of the Emory Vaccine Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-07 |
| Phase | Phase 4 |
What the registry record for NCT07185399 still lists
NCT07185399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 6,755-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 1 intervention - of which Moderna RSV vaccine is the first listed.
NCT07185399 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07185399 about?
NCT07185399 is a clinical study titled "Systems Biological Analysis of Immune Responses to RSV Vaccine". The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach. The study aims to generate high-resolution immunologic and systems biology data following vaccination to identify early biomarkers...
What is the current status of trial NCT07185399?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2025-10-13. Estimated completion is 2026-07.
What conditions does trial NCT07185399 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT07185399?
The interventions under investigation include: Moderna RSV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07185399?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07185399 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus (RSV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07185399's enrollment target sits among peer trials
14 12th of 11 the lowest of 11 other Respiratory Syncytial Virus (RSV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus (RSV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RSV Vaccine Pregnancy Registry
RECRUITING
-
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
RECRUITING · Phase 2
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Transplacental Transmission of RSV (TTRSV)
ACTIVE NOT RECRUITING
-
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy